Seribantumab

N/A

Report date: 2024/09/20 20:00:41

Base Information

Drug NameSeribantumab
Drug Alias Name瑟瑞妥单抗seribantumabum塞本妥人单抗MM-121SAR-256212 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[26] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerrimack Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesElevation Oncology IncSanofiMerrimack Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerSolid tumoursUrinary Bladder Neoplasms +[26] 

Other Information

ATC CodeN/A
Related LinksWikipedia